.
Dan Legault: Yes, we are thrilled, a great company. It was our fourth deal, actually. Yeah, weve licensed otenaproxesul for some 50 countries. China was the largest one. We were, and these things help. They give us validation, they give us non-dilutive money. But now, were now in dialogue for the large markets in the Big Five in Europe, and the United States of course, and Japan. But we were very very pleased with the Chinese deal. First of all, those, the terms were quite attractive that we received. It sort of raised the eyebrows of the industry, because we negotiated quite nice terms. And theyre a great company, they, you know, their CEO more or less built the commercial franchise for AstraZeneca, and he is a South African, but deeply knows the Chinese commercial landscape, which is rapidly evolving, actually. And we received really nice money, plus we have essentially a veto, and its a quite a friendly partnership. But they want and respect our involvement in their clinical trial process, well have to do a Phase III trial in China